Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

‘A cure on the horizon’: Are we finally close to ending type 1 diabetes?

Key Takeaway: The article discusses the promising developments in the treatment of type 1 diabetes, highlighting the potential for a cure. It emphasizes the importance of patient stories and ongoing clinical trials that may lead to significant breakthroughs. The tone is optimistic regarding future advancements in managing this condition.
Price reaction · baseline $3.09 (2026-04-06 close) · hit after-hours · clean, no other ELDN news in the window
day 0 close · peak
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Potential advancements in type 1 diabetes treatment.
  • Hope for a cure on the horizon.
  • Increased focus on patient stories and clinical trials.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the current status of type 1 diabetes treatment?

There are promising developments suggesting a potential cure for type 1 diabetes.

How are patient stories contributing to diabetes research?

Patient stories are being highlighted to emphasize the impact of ongoing clinical trials.

Last updated: Apr 6, 2026